Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Geology researcher wins international photographic contest
2017-06-02

Description: Dr Elizaveta Kovaleva Tags: Dr Elizaveta Kovaleva

In this winning photo, “Movement of the ancient sand”,
Dr Matthew Huber, postdoctoral research fellow in the
Department of Geology at UFS, is scaling an outcrop
of sandstone (former sand dunes) in the Zion National
Park in the US.
Photo: Dr Elizaveta Kovaleva


Dr Elizaveta Kovaleva and Dr Matthew Huber, postdoctoral research fellows in the Department of Geology at the University of the Free State (UFS), attended the European Geosciences Union (EGU) General Assembly in Vienna, Austria in April 2017, where Dr Kovaleva was declared a winner of the EGU photo contest with a photograph entitled “Movement of the ancient sand”.

Submitting the winning photo
Each participant could submit up to three photos to participate in the contest before the conference. From all the photographs 10 were selected and displayed for the entire week at the assembly so participants could vote for their three favourite photos. At the end of the week three winners were selected. The prize winners received a free EGU book of their choice, free registration for next year’s EGU and an option to judge the photo competition next year. The photos will be printed on postcards next year, so all participants can send them wherever they want around the globe.

“The picture was taken in the Zion National Park in the US. Myself and Dr Huber were travelling around the western states, visiting national parks. The person in the picture is Dr Huber,” said Dr Kovaleva.

Dr Kovaleva was also invited to participate - as a recently published author - in a workshop, called: ”Publishing in EGU journals: Solid Earth and Earth Surface Dynamics – Meet the Editors”.

At the assembly, Dr Kovaleva attended sessions on Tectonics and Structural Geology as well as on Geochemistry, Mineralogy, Petrology and Volcanology. These sessions were especially interesting in the scope of her research and are directly related to it. “I am a metamorphic petrologist, and with my PhD, I essentially studied microstructures. At the moment, I am studying the Vredefort impact crater, which has experienced both metamorphism and deformation,” she said.

“The winning photos will be printed on postcards,
so all participants can send them wherever they
want around the globe”.

Building scientific connections
For both researchers, the assembly was an opportunity to meet former colleagues and professors from universities all over the world and shake hands with authors whose papers and work they were familiar with, but had never met in person.

“EGU is a perfect opportunity to build scientific connections and relationships, advertise your research and start new collaborations and projects,” said Dr Kovaleva.

The EGU General Assembly 2017 was a great success, with 4 849 oral, 11 312 poster, and 1 238 PICO presentations. Some 649 unique scientific sessions, together with 88 short courses and 322 side events, created an interesting programme. At the conference 14 496 scientists from 107 countries participated, of whom 53% were under the age of 35. Thirty one were from South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept